Feature|Articles|June 14, 2024
- Pharmaceutical Executive: June 2024
- Volume 44
- Issue 6
Pharmaceutical Executive: June 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive June 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 2 years ago
Beyond the Numbers: Extrapolating Today’s Trends Forwardabout 2 years ago
Opposite Spectrumsabout 2 years ago
2024 Pharm Exec Top 50 Companiesabout 2 years ago
Craig Tooman: Silencing the Distractionsabout 2 years ago
Regaining Trust in the Pharma Industryabout 2 years ago
Succession Attack Plan: Get Strategic with Your Critical Rolesabout 2 years ago
The Healthcare System is Changing—So How Should We Respond?about 2 years ago
Biotech Performance Remains Tethered to Rate Expectationsabout 2 years ago
Pharm Exec Exclusive: Mark Cuban Talks Drug PricingAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series A
2
Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010
3
FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010
4
FDA Approves Utebzi for Adults with Complicated Urinary Tract Infections
5